Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ariel Gonzalez Cordero

Cardiovascular Disease Carolina, PR Medical Doctor

NPI 1376924506 CMS profile 8093717

10,000 Ave. 65 De Infanteria, Carolina Shopping Court Suite 205, Carolina, PR 00985

Open in the dashboard

General payments

$4,321

86 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ariel Gonzalez Cordero of Carolina, PR is reported in the CMS Open Payments database as having received $4,321 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $763 22
2024 General $529 10
2023 General $260 5
2022 General $1,011 23
2021 General $1,166 17
2020 General $593 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ariel Gonzalez Cordero
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ariel Gonzalez Cordero were reported at $763. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ariel Gonzalez Cordero Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $593 $242 $77–$751 $114
2021 $1,166 $335 $101–$1,037 $132
2022 $1,011 $395 $121–$1,211 $149
2023 $260 $443 $136–$1,283 $160
2024 $529 $450 $136–$1,323 $164
2025 $763 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $1,950 18 payments
  2. Abbott Laboratories $932 11 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $550 26 payments
  4. AstraZeneca Pharmaceuticals LP $163 3 payments
  5. Amgen Inc. $143 2 payments
  6. E.R. Squibb & Sons, L.L.C. $141 11 payments
  7. Janssen Pharmaceuticals, Inc $132 3 payments
  8. Medtronic Vascular, Inc. $96 1 payment
  9. Bayer Puerto Rico Inc. $63 3 payments
  10. PBG Puerto Rico LLC $62 4 payments
  11. Other $91 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,321 86 payments
Products named General payments · program years 2020–2025
  1. LifeVest $550 26 payments
  2. AVEIR $329 3 payments
  3. CryoConsole $244 2 payments
  4. NA $240 3 payments
  5. Micra $230 2 payments
  6. VISA AF MRI VR SURESCAN $224 1 payment
  7. Confirm Rx $215 2 payments
  8. COBALT DR MRI SURESCAN $175 1 payment
  9. COREVALVE EVOLUT R $155 1 payment
  10. FARXIGA $151 2 payments
  11. Other $1,861 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,591

Median for Cardiology: 2,533

Drug cost

$157,669

Median for Cardiology: $485,213

Branded share of claims

17.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 64 $56,280
Farxiga Dapagliflozin Propanediol Brand 58 $35,193
Jardiance Empagliflozin Brand 39 $29,938
Xarelto Rivaroxaban Brand 27 $21,125
Rosuvastatin Calcium Generic 235 $2,355
Candesartan Cilexetil Generic 28 $2,036
Losartan Potassium Generic 208 $1,700
Metoprolol Succinate Generic 126 $1,359
Atorvastatin Calcium Generic 150 $1,120
Carvedilol Generic 110 $765

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$11,534

Medicare's payments for the services billed

Medicare patients

82

Average age 76

Services billed

169

50 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Arthritis 45%
Heart failure 41%
Chronic kidney disease 41%
Ischemic heart disease 40%
Atrial fibrillation 33%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record